Cargando…

Is dexamethasone-induced muscle atrophy an alternative model for naturally aged sarcopenia model?

BACKGROUND: Primary sarcopenia is usually known as age-related skeletal muscle loss; however, other factors like endocrine, lifestyle and inflammation can also cause muscle loss, known as secondary sarcopenia. Although many studies have used different sarcopenia animal models for exploring the under...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Belle Yu-Hsuan, Hsiao, Allen Wei-Ting, Wong, Nicodemus, Chen, Yi-Fan, Lee, Chien-Wei, Lee, Wayne Yuk Wai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Speaking Orthopaedic Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793312/
https://www.ncbi.nlm.nih.gov/pubmed/36605620
http://dx.doi.org/10.1016/j.jot.2022.11.005
_version_ 1784859829350694912
author Wang, Belle Yu-Hsuan
Hsiao, Allen Wei-Ting
Wong, Nicodemus
Chen, Yi-Fan
Lee, Chien-Wei
Lee, Wayne Yuk Wai
author_facet Wang, Belle Yu-Hsuan
Hsiao, Allen Wei-Ting
Wong, Nicodemus
Chen, Yi-Fan
Lee, Chien-Wei
Lee, Wayne Yuk Wai
author_sort Wang, Belle Yu-Hsuan
collection PubMed
description BACKGROUND: Primary sarcopenia is usually known as age-related skeletal muscle loss; however, other factors like endocrine, lifestyle and inflammation can also cause muscle loss, known as secondary sarcopenia. Although many studies have used different sarcopenia animal models for exploring the underlying mechanism and therapeutic approaches for sarcopenia, limited study has provided evidence of the relevance of these animal models. This study aims to investigate the similarity and difference in muscle qualities between primary and secondary sarcopenia mice models, using naturally aged mice and dexamethasone-induced mice. METHODS: 21-month-old mice were used as naturally aged primary sarcopenia mice and 3-month-old mice received daily intraperitoneal injection of dexamethasone (20 mg/ kg body weight) for 10 days were used as secondary sarcopenia model. This study provided measurements for muscle mass and functions, including Dual-energy X-ray absorptiometry (DXA) scanning, handgrip strength test and treadmill running to exhaustion test. Besides, muscle contraction, muscle fibre type measurements and gene expression were also performed to provide additional information on muscle qualities. RESULTS: The results suggest two sarcopenia animal models shared a comparable decrease in forelimb lean mass, muscle fibre size, grip strength and muscle contraction ability. Besides, the upregulation of protein degradation genes was also observed in two sarcopenia animal models. However, only primary sarcopenia mice were identified with an early stage of mtDNA deletion. CONCLUSION: Collectively, this study evaluated that the dexamethasone-induced mouse model could be served as an alternative model for primary sarcopenia, according to the comparable muscle mass and functional changes. However, whether dexamethasone-induced mice can be used as an animal model when studying the molecular mechanisms of sarcopenia needs to be carefully evaluated. THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: The purpose of sarcopenia research is to investigate appropriate treatments for reversing the loss of skeletal muscle mass and functions. Using animal models for the preclinical study could predict the safety and efficacy of the treatments. This study compared the typical age-related sarcopenia mice model and dexamethasone-induced secondary sarcopenia mice to provide evidence of the pathological and functional changes in the mice models.
format Online
Article
Text
id pubmed-9793312
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Chinese Speaking Orthopaedic Society
record_format MEDLINE/PubMed
spelling pubmed-97933122023-01-04 Is dexamethasone-induced muscle atrophy an alternative model for naturally aged sarcopenia model? Wang, Belle Yu-Hsuan Hsiao, Allen Wei-Ting Wong, Nicodemus Chen, Yi-Fan Lee, Chien-Wei Lee, Wayne Yuk Wai J Orthop Translat Original Article BACKGROUND: Primary sarcopenia is usually known as age-related skeletal muscle loss; however, other factors like endocrine, lifestyle and inflammation can also cause muscle loss, known as secondary sarcopenia. Although many studies have used different sarcopenia animal models for exploring the underlying mechanism and therapeutic approaches for sarcopenia, limited study has provided evidence of the relevance of these animal models. This study aims to investigate the similarity and difference in muscle qualities between primary and secondary sarcopenia mice models, using naturally aged mice and dexamethasone-induced mice. METHODS: 21-month-old mice were used as naturally aged primary sarcopenia mice and 3-month-old mice received daily intraperitoneal injection of dexamethasone (20 mg/ kg body weight) for 10 days were used as secondary sarcopenia model. This study provided measurements for muscle mass and functions, including Dual-energy X-ray absorptiometry (DXA) scanning, handgrip strength test and treadmill running to exhaustion test. Besides, muscle contraction, muscle fibre type measurements and gene expression were also performed to provide additional information on muscle qualities. RESULTS: The results suggest two sarcopenia animal models shared a comparable decrease in forelimb lean mass, muscle fibre size, grip strength and muscle contraction ability. Besides, the upregulation of protein degradation genes was also observed in two sarcopenia animal models. However, only primary sarcopenia mice were identified with an early stage of mtDNA deletion. CONCLUSION: Collectively, this study evaluated that the dexamethasone-induced mouse model could be served as an alternative model for primary sarcopenia, according to the comparable muscle mass and functional changes. However, whether dexamethasone-induced mice can be used as an animal model when studying the molecular mechanisms of sarcopenia needs to be carefully evaluated. THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: The purpose of sarcopenia research is to investigate appropriate treatments for reversing the loss of skeletal muscle mass and functions. Using animal models for the preclinical study could predict the safety and efficacy of the treatments. This study compared the typical age-related sarcopenia mice model and dexamethasone-induced secondary sarcopenia mice to provide evidence of the pathological and functional changes in the mice models. Chinese Speaking Orthopaedic Society 2022-12-20 /pmc/articles/PMC9793312/ /pubmed/36605620 http://dx.doi.org/10.1016/j.jot.2022.11.005 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Wang, Belle Yu-Hsuan
Hsiao, Allen Wei-Ting
Wong, Nicodemus
Chen, Yi-Fan
Lee, Chien-Wei
Lee, Wayne Yuk Wai
Is dexamethasone-induced muscle atrophy an alternative model for naturally aged sarcopenia model?
title Is dexamethasone-induced muscle atrophy an alternative model for naturally aged sarcopenia model?
title_full Is dexamethasone-induced muscle atrophy an alternative model for naturally aged sarcopenia model?
title_fullStr Is dexamethasone-induced muscle atrophy an alternative model for naturally aged sarcopenia model?
title_full_unstemmed Is dexamethasone-induced muscle atrophy an alternative model for naturally aged sarcopenia model?
title_short Is dexamethasone-induced muscle atrophy an alternative model for naturally aged sarcopenia model?
title_sort is dexamethasone-induced muscle atrophy an alternative model for naturally aged sarcopenia model?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793312/
https://www.ncbi.nlm.nih.gov/pubmed/36605620
http://dx.doi.org/10.1016/j.jot.2022.11.005
work_keys_str_mv AT wangbelleyuhsuan isdexamethasoneinducedmuscleatrophyanalternativemodelfornaturallyagedsarcopeniamodel
AT hsiaoallenweiting isdexamethasoneinducedmuscleatrophyanalternativemodelfornaturallyagedsarcopeniamodel
AT wongnicodemus isdexamethasoneinducedmuscleatrophyanalternativemodelfornaturallyagedsarcopeniamodel
AT chenyifan isdexamethasoneinducedmuscleatrophyanalternativemodelfornaturallyagedsarcopeniamodel
AT leechienwei isdexamethasoneinducedmuscleatrophyanalternativemodelfornaturallyagedsarcopeniamodel
AT leewayneyukwai isdexamethasoneinducedmuscleatrophyanalternativemodelfornaturallyagedsarcopeniamodel